RESEARCH ARTICLE

Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010–2018

Antoine Meyer1,2,3*, Marion Fermaut4, Jérôme Drouin1, Franck Carbonnel2,3, Alain Weill1

1 GIS-EPIPHARE, Épidémiologie des produits de santé, ANSM-CNAM, 42 bd de la Libération, Saint Denis, France, 2 Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France, 3 Université Paris Sud, Le Kremlin Bicêtre, France, 4 Assistance Publique-Hôpitaux de Paris, Hôpital Jean Verdier, Bondy, France

* antoinemeyer@gmail.com

Abstract

Purpose
To describe drug prescription for gastrointestinal symptoms during pregnancy.

Methods
Using the French national health database, we identified pregnancies ending with a birth between April 2010 and December 2018, in France. We studied prescription of antacids, antispasmodics, antinauseants, laxatives and antidiarrheals during pregnancy, between two trimesters before and two trimesters after delivery. We also assessed hospitalization for gastrointestinal symptoms during pregnancy.

Results
Among 6,365,471 pregnancies, 4,452,779 (74.0%) received at least one gastrointestinal drug during pregnancy; 2,228,275 (37.0%) received an antacid, 3,096,858 (51.5%) an antispasmodic, 1,861,731 (31.0%) an antinauseant, 919,116 (15.3%) a laxative and 617,808 (10.3%) an antidiarrheal. Prescription of proton pump inhibitors doubled from 12.2% in 2010 to 26.0% in 2018, while domperidone use decreased from 18.3% in 2010 to 2.2% in 2018. In addition, prescription of antacids increased from 7.0% during the trimester before pregnancy to 11.8% during the 1st trimester, 17.0% during the 2nd trimester and 23.4% during the 3rd trimester. Antispasmodic use was 10.6% during the trimester before pregnancy, 23.1% during the 1st trimester, 25.2% during the 2nd trimester and 24.0% during the 3rd trimester. Prescription of antinauseant drugs increased from 5.0% during the trimester before pregnancy to 25.7% during the 1st trimester, then decreased to 6.4% during the 2nd trimester and 3.2% during the 3rd trimester. Nausea/vomiting was the most common cause of hospitalization for gastrointestinal symptoms or diseases during pregnancy, although it accounted for only 1.0% of pregnancies.
Conclusions

Approximately three-quarters of women use drugs for gastrointestinal symptoms during pregnancy in France. Prescription of gastrointestinal drugs during pregnancy should be the subject of more detailed risk-benefit assessment and recommendations.

Background and aims

Thalidomide was used as an antinauseant medication during pregnancy until its teratogenic effect was demonstrated in the 1960s. This scandal led to an increased awareness of the safe use of drugs during pregnancy [1]. Yet, data on the safety of drugs used during pregnancy (for women and offspring) is often lacking as pre-marketing clinical trials exclude pregnant women. Observational studies are therefore essential to study the efficacy and safety drugs in pregnant women and their offspring. For instance, a French nationwide study on recent data confirmed that valproic acid, a treatment for epilepsy, cause birth defects and delayed cognitive development [2, 3].

Despite the concerns about the safety of medication use during pregnancy, many women take medication during pregnancy, but with considerable variability according to geographical region and over time [4, 5]. In recent years, between 58% and 97% of women take at least one medication during pregnancy, depending on the country [4–7]. Gastrointestinal symptoms are common during pregnancy: 50 to 90% of pregnant women experience nausea and 30–80% experience heartburn [8, 9]. No study has specifically assessed the use of the various classes of gastrointestinal drugs during pregnancy, as these drugs are often grouped into a single category of gastrointestinal drugs [4, 6, 7, 10, 11]. Drug use studies in pregnancy are useful to identify the most frequently used drugs and thereby decide which drug safety studies should be prioritized.

The aim of the present study was to describe drug use for gastrointestinal symptoms during pregnancy in a large-scale, population-based, nationwide study between 2010 and 2018 using the French national health data system, in a partnership between clinicians, French national health insurance (Caisse Nationale d’Assurance Maladie) and the French National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament).

Materials and methods

Data source

The French national health data system (Système National des Données de Santé, SNDS) covers more than 99% of the French population (around 66,000,000 people). Each person is identified by a unique, anonymous number. The SNDS contains all outpatient information (demographics, drugs dispensed, and procedures) and all inpatient information (expensive drugs dispensed, procedures performed during hospital stays, and diagnoses) [12]. Studies based on this database have produced meaningful results in recent years [13–17].

We adapted an algorithm previously developed and used [16, 18] to identify pregnancies ending between April 1, 2010 and December 31, 2018 among women aged 15 to 49 in the SNDS (S1 Table). The pregnancy end date was the date of delivery, or, when missing, the date of admission for pregnancy completion. The pregnancy start date was calculated using gestational age at the end of pregnancy, or, when missing, the date of the last menstrual period entered by the physician at the end of pregnancy [19].

Future researchers can request access via the Health data hub: (https://documentation-snds.health-data-hub.fr/introduction/03-acces-snds.html#les-acces-sur-projet).

Funding: The author(s) received no specific funding for this work.

Competing interests: Conflict of Interest: - Antoine Meyer: no conflict of interest. - Marion Fermaut: no conflict of interest. - Jérôme Droin: no conflict of interest. - Franck Carbonnel: received honoraria from Amgen, BMS, Celltrion, Enterome, Ferring, Janssen, Medtronic, Pfizer, Pharmacosmos, Roche and Tillotts as well as lecture fees from Abbvie, Astra, BMS, Ferring, Janssen, MSD, Pfizer, Pileje, and Takeda. - Alain Weill: no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Study population

All pregnancies ending with a birth—either livebirth—between April 2010 and December 2018 were included. A stillbirth was the delivery of a dead fetus after 22 weeks of amenorrhea (referred to as weeks thereafter). We excluded pregnancies with elective or therapeutic abortions, spontaneous abortions, ectopic pregnancies and hydatidiform moles and other abnormal products of conception (blighted ovum and nonhydatidiform moles), because to study drug exposure throughout pregnancy, pregnancies that last three trimesters are needed. Pregnant women with no healthcare record in the SNDS database during the 2 years preceding the pregnancy were excluded. These women may have lived outside of France or their outpatient data may have been unavailable in the SNDS (less than 1% of the French population).

Drug exposure and hospitalizations

We studied each drug dispensed for gastrointestinal symptoms including: antacids, antispasmodics, antinauseants, laxatives, antidiarrheals and other drugs for functional gastrointestinal disorders. Details on International Non-Proprietary name and Anatomical Therapeutic Chemical Classification are given in S2 Table. For each pregnancy, seven trimesters were studied: two trimesters before the beginning of pregnancy (Trim-2: day −182 to day −92; Trim-1: day −91 to day −1), each trimester of pregnancy (Trim1: day 0 i.e. fertilisation to day 90; Trim2: day 91 to day 181; Trim3: day 182 to delivery −1) and two trimesters after the end of pregnancy (Trim+1: delivery to delivery + 91; Trim+2: delivery + 92 to delivery + 182). A pregnancy trimester was considered to be exposed to a drug when this drug was dispensed at least once during this trimester. We also grouped these drugs into a single category to study the rate of pregnant women using at least one gastrointestinal drug. Additionally, we looked at the dispensing rates of drugs in the Anatomical Therapeutic Chemical (ATC) classes A02 to A09 to allow more reliable comparison with published data.

We also studied the most common reasons for hospitalization for a gastrointestinal symptom or disease between two trimesters before and two trimesters after pregnancy, including: nausea/vomiting, cholestasis, proctological disease (fissure, fistula, abscess, hemorrhoids), appendicitis and biliary diseases (S3 Table).

Maternal and pregnancy characteristics

Baseline maternal characteristics included: age, Complementary Universal Health Insurance status (free access to health care for people with low income), a deprivation index expressed in quintiles that was developed in France as the first component of a principal component analysis of 4 socioeconomic variables [20], and income (general health insurance scheme: none, <€2,000/month, ≥€2,000/month; and agricultural/self-employed scheme) calculated from the woman’s salary during the three months before maternity leave. Gravidity (1st pregnancy, 2nd pregnancy, . . . ) was defined as the pregnancy number in a woman during the study period. Assisted reproduction was defined as any of the following procedures performed in France during the two months preceding pregnancy: ovarian stimulation, oocyte retrieval, artificial insemination or in vitro fertilization. The clinical setting of termination of pregnancy was recorded: university hospital, general hospital, private hospital, or outpatient procedure.

Pregnancy characteristics included type of delivery (cesarean or vaginal), vital status at birth (livebirth or stillbirth), prematurity (births occurring before 37 weeks were considered to be preterm and those occurring before 32 weeks were considered to be very preterm) and birth weight for gestational age (below the 10th percentile and above the 90th percentile of the gestational age computed in the national pregnancy cohort were considered small and large.
for gestational age, respectively). Birth weight was available for those infants in whom linkage between mother and child data was available (78.5% of pregnancies with delivery).

**Statistical analysis**

The unit of analysis was a pregnancy, i.e. all of a patient’s pregnancies were included in the analysis. We first described maternal characteristics at the beginning of pregnancy and pregnancy characteristics for each pregnancy: median and interquartile range (IQR) for continuous variables and proportions for categorical variables. Medication dispensing during pregnancy over time was then described for pregnancy ending between April 2010 and December 2018: crude numbers and percentages of exposed pregnancies by year of pregnancy end. Medication dispensing and hospitalizations before, during and after pregnancy was described for pregnancies ending between April 2010 and June 2018: crude numbers and percentages of exposed pregnancies by trimester. A sensitivity analysis was performed and excluded pregnancies of less than 37 weeks.

All analyses were performed with SAS® software version 9.4 (SAS Institute, North Carolina, USA). The French public institution which conducted this study has permanent access to the SNDS database in application of the provisions of Articles R. 1461–12 et seq. of the French Public Health Code and the French data protection authority decision CNIL-2016-316. No informed consent was therefore required. This research did not receive any funding.

**Results**

**Study population**

Among approximately 32 million women in France, 4,546,505 completed a pregnancy between April 1, 2010 and December 31, 2018. A total of 8,796,626 pregnancies were identified among these women. The following pregnancies were excluded: 1,687,516 elective/therapeutic abortions, 339,553 spontaneous abortions, 96,073 ectopic pregnancies, 110,902 hydatidiform moles or other abnormal products of conception and 197,111 with no prior outpatient health care utilization during the 2 years before pregnancy. A total of 6,365,471 pregnancies ending with delivery were therefore included (S1 Fig). The annual number of pregnancies decreased slightly from 763,069 in 2011 to 682,065 in 2018 (S2 Fig).

**Maternal and pregnancy characteristics**

Maternal and pregnancy characteristics are presented in Table 1. Median age at the beginning of pregnancy was 29 years (IQR: 26–33), 809,034 (12.7%) women had Complementary Universal Health Insurance cover, 2,508,345 (39.4%) had no income and 174,174 (2.7%) had undergone assisted reproduction. Pregnancies ended with 1,273,816 (20.0%) cesarean sections, 32,677 (0.5%) stillbirths, 352,817 (5.5%) preterm births, 73,135 (1.2%) very preterm births and the mean birth weight was 3.29 kg (IQR: 2.98–3.61).

**Drug exposure**

Among all pregnancies with delivery, 4,452,779 (74.0%) received at least one gastrointestinal drug during pregnancy; 2,228,275 (37.0%) pregnancies were exposed to an antacid, 3,096,858 (51.5%) to an antispasmodic, 1,861,731 (31.0%) to an antinauseant, 919,116 (15.3%) to a laxative and 617,808 (10.3%) to an anti-diarrheal (Table 2). The antispasmodic phloroglucinol was by far the most commonly prescribed drug (51.0% of all pregnancies). These rates of drug exposure during pregnancy were consistent over ages at the beginning of pregnancy and excluding pregnancies of less than 37 weeks (S3 Fig and S4 Table). However, drug use was
slightly higher in more deprived pregnancies than in less deprived pregnancies (76.0% vs 72.3% for at least one gastrointestinal drug use), and this applied to most of the drugs studied (S4 Fig).
Drug exposure over time

The percentage of women who received at least one gastrointestinal drug during pregnancy varied little over time (75.2% in 2010 to 72.0% in 2018). However, exposure to several drugs changed over the study period (Fig 1). Antacid use increased from 34.0% in 2010 to 39.0% in 2018 mainly due to increased use of proton pump inhibitors from 12.2% in 2010 to 26.0% in 2018, while the use of locally-acting antacids and histamine 2 blockers decreased slightly from 27.1% and 2.4% in 2010 to 24.0% and 1.3% in 2018, respectively (Fig 2). Antinauseant drug use decreased from 37.8% in 2010 to 25.2% in 2018, mainly due to decreased use of domperidone (18.3% in 2010 to 2.2% in 2018), while 5-HT3 antagonists use increased from 0.02% in 2010 to 0.4% in 2018 (S5 Fig). Antispasmodic and laxative exposure did not change from 2010 to 2018.

Table 2. Drug exposure before, during and after pregnancy (thousands).

| Number of pregnancies, thousands (%) | Trim-2 | Trim-1 | Trim1 | Trim2 | Trim3 | Trim123 | Trim+1 | Trim+2 |
|--------------------------------------|--------|--------|-------|-------|-------|---------|--------|--------|
| Number of pregnancies                | 6,015  | 6,015  | 6,015 | 6,015 | 5,985 | 6,015   | 6,015  | 6,015  |
| Antacids                             | 448 (7.4) | 420 (7.0) | 711 (11.8) | 1,022 (17.0) | 1,400 (23.4) | 2,228 (37.0) | 469 (7.8) | 363 (6.0) |
| Locally-acting                       | 115 (1.9) | 104 (1.7) | 449 (7.5) | 674 (11.2) | 808 (13.5) | 1,541 (25.6) | 107 (1.8) | 97 (1.6) |
| Histamine 2 blocker                  | 11 (0.2) | 10 (0.2) | 21 (0.3) | 45 (0.7) | 78 (1.3) | 118 (2.0) | 7 (0.1) | 7 (0.1) |
| Proton pump inhibitor                | 379 (6.3) | 360 (6.0) | 371 (6.2) | 465 (7.7) | 753 (12.6) | 1,188 (19.7) | 396 (6.6) | 303 (5.0) |
| Antacids                             | 448 (7.4) | 420 (7.0) | 711 (11.8) | 1,022 (17.0) | 1,400 (23.4) | 2,228 (37.0) | 469 (7.8) | 363 (6.0) |
| Mebeverine                           | 10 (0.2) | 10 (0.2) | 4 (0.1) | 1 (0.0) | 1 (0.0) | 6 (0.1) | 4 (0.1) | 5 (0.1) |
| Trimebutine                          | 85 (1.4) | 84 (1.4) | 45 (0.8) | 21 (0.3) | 9 (0.2) | 72 (1.2) | 73 (1.2) | 63 (1.0) |
| Pinaverium                           | 12 (0.2) | 12 (0.2) | 4 (0.1) | 1 (0.0) | 0 (0.0) | 5 (0.1) | 4 (0.1) | 7 (0.1) |
| Phloroglucinol                       | 534 (8.9) | 527 (8.8) | 1,346 (22.4) | 1,499 (24.9) | 1,427 (23.8) | 3,065 (51.0) | 1,293 (21.5) | 435 (7.2) |
| Metoclopramide                       | 321 (5.3) | 298 (5.0) | 1,548 (25.7) | 385 (6.4) | 191 (3.2) | 1,862 (31.0) | 156 (2.6) | 249 (4.1) |
| Domperidone                          | 162 (2.7) | 149 (2.5) | 511 (8.5) | 114 (1.9) | 56 (0.9) | 634 (10.5) | 84 (1.4) | 110 (1.8) |
| Metopimazine                         | 122 (2.0) | 117 (2.0) | 492 (8.2) | 118 (2.0) | 58 (1.0) | 622 (10.3) | 12 (0.2) | 2 (0.1) |
| 5-HT3 antagonists                    | 0 (0.0) | 0 (0.0) | 7 (0.1) | 3 (0.0) | 1 (0.0) | 8 (0.1) | 1 (0.0) | 1 (0.0) |
| Others                               | 11 (0.2) | 10 (0.2) | 8 (0.1) | 3 (0.1) | 1 (0.0) | 12 (0.2) | 4 (0.1) | 6 (0.1) |
| Laxatives                            | 141 (2.4) | 132 (2.2) | 370 (6.2) | 381 (6.3) | 353 (5.9) | 919 (15.3) | 438 (7.3) | 127 (2.1) |
| Metoclopramide                       | 50 (0.8) | 42 (0.7) | 805 (13.4) | 170 (2.8) | 83 (1.4) | 971 (16.1) | 22 (0.4) | 35 (0.6) |
| Domperidone                          | 162 (2.7) | 149 (2.5) | 511 (8.5) | 114 (1.9) | 56 (0.9) | 634 (10.5) | 84 (1.4) | 110 (1.8) |
| Metopimazine                         | 122 (2.0) | 117 (2.0) | 492 (8.2) | 118 (2.0) | 58 (1.0) | 622 (10.3) | 12 (0.2) | 2 (0.1) |
| 5-HT3 antagonists                    | 0 (0.0) | 0 (0.0) | 7 (0.1) | 3 (0.0) | 1 (0.0) | 8 (0.1) | 1 (0.0) | 1 (0.0) |
| Others                               | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) | 1 (0.0) |
| Antidiarrheals                       | 275 (4.6) | 263 (4.4) | 287 (4.8) | 230 (3.8) | 141 (2.4) | 618 (10.3) | 158 (2.6) | 244 (4.1) |
| Loperamide                           | 98 (1.6) | 93 (1.5) | 72 (1.2) | 52 (0.9) | 32 (0.5) | 151 (2.5) | 47 (0.8) | 76 (1.3) |
| Raltezolamide                        | 110 (1.8) | 106 (1.8) | 45 (0.7) | 20 (0.3) | 10 (0.2) | 74 (1.2) | 54 (0.9) | 101 (1.7) |
| Diosmectite                          | 120 (2.0) | 115 (1.9) | 205 (3.4) | 180 (3.0) | 112 (1.9) | 473 (7.9) | 85 (1.4) | 113 (1.9) |
| Ursodeoxycholic acid                 | 2 (0.0) | 2 (0.0) | 1 (0.0) | 2 (0.0) | 21 (0.3) | 22 (0.4) | 2 (0.0) | 2 (0.0) |
| All gastrointestinal drugs           | 1,197 (19.9) | 1,147 (19.1) | 2,625 (43.6) | 2,452 (40.8) | 2,603 (43.5) | 4,453 (74.0) | 2,003 (33.3) | 1,006 (16.7) |
| ATC A02-A09                          | 1,208 (20.1) | 1,158 (19.3) | 2,630 (43.7) | 2,457 (40.8) | 2,608 (43.6) | 4,456 (74.1) | 2,018 (33.5) | 1,018 (16.9) |

Medication dispensing before, during and after pregnancy was described for pregnancies ending between April 2010 and June 2018: crude numbers and percentages of exposed pregnancies by trimester. As other drugs for functional gastrointestinal disorders represented <0.1% for each trimester, they were not reported. ATC: Anatomical Therapeutic Chemical.

https://doi.org/10.1371/journal.pone.0245854.t002
Antidiarrheal drug use decreased slightly from 11.7% in 2010 to 8.9% in 2018, mainly due to decreased use of diosmectite (9.3% in 2010 to 6.4% in 2018) (S8 Fig).

Drug exposure before, during and after pregnancy

All drug exposures varied during the course of the pregnancy. Antacid use increased from 7.0% during the trimester before pregnancy to 11.8% during the 1st trimester, 17.0% during the 2nd trimester and 23.4% during the 3rd trimester. Antispasmodic use increased from 10.6% during the trimester before pregnancy to 23.1% during the 1st trimester, 25.2% during the 2nd trimester and 24.0% during the 3rd trimester. Antinauseant use increased from 5.0% during the trimester before pregnancy to 25.7% during the 1st trimester, and then decreased to 6.4% during the 2nd trimester and 3.2% during the 3rd trimester. Laxative use increased from 2.2% during the trimester before pregnancy to 6.2% during the 1st trimester, 6.3% during the 2nd
trimester and 5.9% during the 3\textsuperscript{rd} trimester (Table 2 and Fig 3). These variations in exposure during the course of pregnancy were consistent over age at the beginning of pregnancy, deprivation index and excluding pregnancies lasting less than 37 weeks (S2 and S3 Figs and S4 Table).

**Hospitalizations**

Nausea/vomiting was the most common cause of hospitalization for gastrointestinal symptoms or diseases during pregnancy, although it accounted for only 1.0% of pregnancies, mainly during the 1\textsuperscript{st} trimester (0.7%). Hospitalization for cholestasis occurred in 0.3% of pregnancies, mainly in the 3\textsuperscript{rd} trimester (0.3%). The other causes of hospitalization each represented less than 0.2% of pregnancies (Table 3).

**Discussion**

This population-based, nationwide study of 6,365,471 pregnancies in France from 2010 to 2018 shows that, during pregnancy, approximately three-quarters of women use drugs for
gastrointestinal symptoms: approximately one-half of pregnancies are exposed to antispasmodics, and one-third are exposed to antacids and antinauseants. From 2010 to 2018, the use of proton pump inhibitors doubled, while the use of histamine 2 blockers decreased. Prescription of antacids increased during the course of pregnancy, while antinauseants were mainly

Table 3. Hospitalizations before, during and after pregnancy (thousands).

|                      | Trim-2 | Trim-1 | Trim1 | Trim2 | Trim3 | Trim123 | Trim+1 | Trim+2 |
|----------------------|--------|--------|-------|-------|-------|---------|--------|--------|
| Number of pregnancies| 6 015  | 6 015  | 6 015 | 6 015 | 5 985 | 6 015   | 6 015  | 6 015  |
| Nausea/vomiting      | 1 (0.0)| 0 (0.0)| 45 (0.7)| 10 (0.2)| 9 (0.2)| 60 (1.0)| 0 (0.0)| 0 (0.0) |
| Cholestasis          | 0 (0.0)| 0 (0.0)| 0 (0.0)| 1 (0.0)| 18 (0.3)| 19 (0.3)| 10 (0.2)| 0 (0.0) |
| Proctologic disease  | 3 (0.1)| 3 (0.1)| 1 (0.0)| 1 (0.0)| 7 (0.1)| 9 (0.2)| 8 (0.1)| 4 (0.1) |
| Appendicitis         | 3 (0.0)| 2 (0.0)| 2 (0.0)| 1 (0.0)| 0 (0.0)| 3 (0.0)| 3 (0.0)| 2 (0.0) |
| Biliary tract disease| 6 (0.1)| 5 (0.1)| 2 (0.0)| 2 (0.0)| 1 (0.0)| 5 (0.1)| 14 (0.2)| 14 (0.2)|

Hospitalizations before, during and after pregnancy was described for pregnancies ending between April 2010 and June 2018: crude numbers and percentages of exposed pregnancies by trimester.

https://doi.org/10.1371/journal.pone.0245854.t003
prescribed during the first trimester. Hospitalizations for gastrointestinal diseases were rare, most commonly because of vomiting in 1.0% of pregnancies.

We found that approximately three-quarters of women used drugs for gastrointestinal symptoms during pregnancy. This rate is higher than those reported elsewhere: 4 to 13% in Italy [5, 11], 6% in Ireland [21], 7% in British Columbia [10], 9% in Sweden [7], 8 to 34% in the United States of America [6, 22] and 44% in a worldwide web-based study [23]. Gastrointestinal drug use was already high in 1996 in France, as 69% of women took at least one drug during pregnancy [24, 25]. However, the comparison between countries might be biased by differences in terms of recording of the use, availability and reimbursement of drugs, as well as treatment traditions [26]. Gastrointestinal drugs are widely used in France apart from the context of pregnancy. In 2016, 45% of patients between the ages of 18 and 34 years used at least one gastrointestinal drug, 19% used at least one antacid, 16% used antispasmodics, 7% used antinauseants, 3% used laxatives and 8% used antidiarrheal drugs [27]. These drugs were therefore used more frequently during pregnancy. In addition, the type of drug used during pregnancy is not the same around the world; for example, in some countries, H1 anti-histamines are used as a first line of treatment for nausea while this drug class is not used in France for this indication [28]. We found that drug use was only 5% higher in more deprived pregnancies than in less deprived pregnancies (76.0% vs 72.3% for at least one gastrointestinal drug use); other studies have reported a similar trend, but with more marked differences (around 30%) [23, 29, 30].

Domperidone use decreased from 18.3% in 2010 to 2.2% in 2018, which can be explained by the publication of two studies in 2010 that showed that domperidone prolongs the QT interval, and may cause life-threatening arrhythmias [31, 32]. Metopimazine use decreased in 2015 due to a drug company stock shortage [33].

As pre-marketing clinical trials exclude pregnant women, observational studies are therefore essential to study the efficacy and safety drugs in pregnant women and their offspring. Prescription of proton pump inhibitors doubled between 2010 and 2018 in pregnant women. This increase is of the same order of magnitude as that observed in the general population [34–36]. The efficacy of proton pump inhibitors for the relief of heartburn during pregnancy has not been demonstrated [37] and these drugs should be reserved to women not relieved by lifestyle modification [9, 38]. Several studies [9, 39–41] on the safety of use of proton pump inhibitors during pregnancy are reassuring. However, a recent meta-analysis including 26 observational studies suggested that these drugs were associated with an increased risk of congenital malformations (OR 1.28; 95%CI: 1.09–1.52) [42]. Moreover, toxic effects on animal embryos and fetuses are observed with high doses of omeprazole [43]. The two drugs most commonly used for nausea during pregnancy are dopamine antagonists: metoclopramide and metopimazine. Although metoclopramide has been shown to be effective and safe during pregnancy [9, 28, 44], this is not the case for metopimazine. French recommendations indicate that the use of metopimazine should only be considered after failure of other validated treatments, including metoclopramide and 5-HT3 antagonists [45]. Altogether, these data suggest that a more detailed risk-benefit assessment of prescription during pregnancy is necessary, particularly for proton pump inhibitors and metopimazine which are frequently used during pregnancy.

This study has certain limitations. First, like previously published studies based on the SNDS databases, algorithms rather than clinical data were used to identify pregnancies [2, 16]. Nevertheless, the validity of endpoints such as pregnancy outcomes, maternal age, type of delivery, pregnancy duration and birth weight has previously been demonstrated [16, 19, 46]. Second, over-the-counter drugs or drugs prescribed but not reimbursed (e.g. doxylamine) are not included in the SNDS, leading to underestimation of already high rates. Third, a dispensed
drug does not mean that it has been used. However, studying dispensed drugs and not prescriptions avoids primary non-compliance, i.e., that the patient does not redeem the prescription.

The present study also has a number of major strengths. First, it is based on a large and unselected cohort of women with a pregnancy during recent years. Second, the SNDS is a comprehensive database for drug dispensing, covering more than 99% of the French population (around 66,000,000 people).

In conclusion, this large-scale population-based study shows that approximately three-quarters of women are exposed to drugs for gastrointestinal symptoms. From 2010 to 2018, the use of proton pump inhibitors doubled. The benefits and risks associated with increased exposure to proton pump inhibitors during pregnancy need to be further investigated.

**Supporting information**

S1 Fig. Flow-chart.
(TIF)

S2 Fig. Number of pregnancies over time.
(TIF)

S3 Fig. Drug exposure before, during and after pregnancy by the mother’s age at the beginning of pregnancy. A: 15–24 years; B: 25–34 years; C: 35-49 years. Trim: trimester.
(TIF)

S4 Fig. Drug exposure before, during and after pregnancy by deprivation index. A: quintile 1 (less deprived); B: quintile 2–4; C: quintile 5 (more deprived). The deprivation index expressed in quintiles was developed in France as the first component of a principal component analysis of 4 socioeconomic variables. Trim: trimester.
(TIF)

S5 Fig. Ant nauseant exposure during pregnancy over time.
(TIF)

S6 Fig. Antispasmodic exposure during pregnancy over time.
(TIF)

S7 Fig. Laxative exposure during pregnancy over time.
(TIF)

S8 Fig. Antidiarrheal exposure during pregnancy over time.
(TIF)

S1 Table. Pregnancy identification algorithms.
(DOCX)

S2 Table. Drugs.
(DOCX)

S3 Table. Hospitalization for gastrointestinal diseases.
(DOCX)

S4 Table. Drug exposure (thousands): Sensitivity analysis excluding pregnancies lasting less than 37 weeks.
(DOCX)
Acknowledgments
The authors would like to thank Anthony Saul, MD, for assistance with English grammar and spelling.

Author Contributions

Conceptualization: Antoine Meyer, Alain Weill.
Data curation: Jérôme Drouin.
Formal analysis: Antoine Meyer.
Methodology: Antoine Meyer, Jérôme Drouin, Alain Weill.
Supervision: Franck Carbonnel, Alain Weill.
Validation: Antoine Meyer, Marion Fermaut, Franck Carbonnel, Alain Weill.
Writing – original draft: Antoine Meyer.
Writing – review & editing: Antoine Meyer, Marion Fermaut, Franck Carbonnel, Alain Weill.

References

1. Mcbride WG. Thalidomide and congenital abnormalities. The Lancet. 1961; 278: 1358. https://doi.org/10.1016/S0140-6736(61)90927-8
2. Bliotière P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019; 93: e167–e180. https://doi.org/10.1212/01.wnl.0000000000007696 PMID: 31189695
3. Coste J, Bliotière P-O, Miranda S, Mikaeloff Y, Peyre H, Ramus F, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep. 2020; 10. https://doi.org/10.1038/s41598-020-74409-x PMID: 33093466
4. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011; 205: 51.e1–51.e8. https://doi.org/10.1016/j.ajog.2011.02.029 PMID: 21514588
5. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol. 2008; 64: 1125–1132. https://doi.org/10.1007/s00228-008-0546-y PMID: 18685836
6. Haas DM, Marsh DJ, Dang DT, Parker CB, Wing DA, Simhan HN, et al. Prescription and Other Medication Use in Pregnancy: Obstet Gynecol. 2018; 131: 789–798. https://doi.org/10.1097/AOG.0000000000002579 PMID: 29830018
7. Stephansson O, Granath F, Svensson T, Haglund B, Ekborn A, Kieler H. Drug use during pregnancy in Sweden—assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol. 2011; 43. https://doi.org/10.2147/CLEP.S16305 PMID: 21386973
8. Body C, Christie JA. Gastrointestinal Diseases in Pregnancy. Gastroenterol Clin North Am. 2016; 45: 267–283. https://doi.org/10.1016/j.gtc.2016.02.005 PMID: 27261898
9. van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut. 2014; 63: 1014–1023. https://doi.org/10.1136/gutjnl-2013-305418 PMID: 24429582
10. Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001–2006). Clin Ther. 2012; 34: 239–249.e2. https://doi.org/10.1016/j.clinthera.2011.11.025 PMID: 22169049
11. Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol. 2000; 56: 323–328. https://doi.org/10.1007/s002280000149 PMID: 10954347
12. Tuppin P, Rudant J, Constantintou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017; 65 Suppl 4: S149–S167. https://doi.org/10.1016/j.respe.2017.05.004 PMID: 28756037
13. Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. Ann Intern Med. 2018; 170: 99–107. https://doi.org/10.7326/M18-1512 PMID: 30534946

14. Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment Pharmacol Ther. 2017; 45: 37–49. https://doi.org/10.1111/apt.13835 PMID: 27781286

15. Weill A, Dalichamp M, Raguideau F, Ricordeau P, Blotière P-O, Rudant J, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016; 353. https://doi.org/10.1136/bmj.i2002 PMID: 27164970

16. Blotière P-O, Weill A, Dalichamp M, Billionnet C, Mezarobba M, Raguideau F, et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: An application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacopédiémiol Drug Saf. 2018; 27: 763–770. https://doi.org/10.1002/pds.3976 PMID: 29763992

17. Bérand A, Abbas-Chorfa F, Kassai B, Vial T, Nguyen KA, Sheehy O, et al. The French Pregnancy Cohort: Medication use during pregnancy in the French population. Lupattelli A, editor. PLOS ONE. 2019; 14: e0219095. https://doi.org/10.1371/journal.pone.0219095 PMID: 31314794

18. Meyer A, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010–2018. Aliment Pharmacol Ther. n.v. https://doi.org/10.1111/apt.13664 PMID: 33059502

19. Quantin C, Cottenet J, Vaugnat A, Prunet C, Mouquet M-C, Fresson J, et al. Qualité des données périménales issues du PMSI: comparaison avec l’état civil et l’enquête nationale périménales 2010. J Gynécologie Obstétrique Biol Reprod. 2014; 43: 680–690. https://doi.org/10.1016/j.jgyn.2013.09.004 PMID: 24135017

20. Rey G, Jouglia E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009; 9: 33. https://doi.org/10.1186/1471-2458-9-33 PMID: 19161613

21. Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women: MEDICATION USE IN EARLY PREGNANCY. Pharmacopédiémiol Drug Saf. 2010; 19: 408–417. https://doi.org/10.1002/pds.1906 PMID: 20099251

22. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004; 191: 398–407. https://doi.org/10.1016/j.ajog.2004.04.025 PMID: 15343213

23. Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014; 4: e004365. https://doi.org/10.1136/bmjopen-2013-004365 PMID: 24534260

24. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc J. Prescription of drugs during pregnancy in France. The Lancet. 2000; 356: 1735–1736. https://doi.org/10.1016/s0140-6736(00)03209-8 PMID: 11095263

25. Damase-Michel C, Lacroix I, Hurault-Delarue C, Beau A-B, Montastruc J-L. Évaluation des médicaments chez la femme enceinte: à propos de la base de données française EFEMERIS. Therapies. 2014; 69: 91–100. https://doi.org/10.2515/therapie/2014005 PMID: 24698193

26. Bégar B. Les données de vie réelle, un enjeu majeur pour la qualité des soins et la régulation du système de santé L'exemple du médicament. [cited 14 Sep 2020]. Available: https://solidarites-sante.gouv.fr/IMG/pdf/rapport_donnees_de_vie_reelle_medicaments_mai_2017v.pdf

27. Tuppin P, Rivière S, Deutsch D, Gastaldi-Menager C, Sabaté J-M. Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants. Ther Adv Gastroenterol. 2019; 12: 1756284819853790 PMID: 31320929

28. McParlin C, O’Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, et al. Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. JAMA. 2016; 316: 1392. https://doi.org/10.1001/jama.2016.14337 PMID: 27701665

29. Olesen C, Thran N, Henriksen TB, Ehrenstein V, Olsen J. Associations between socio-economic factors and the use of prescription medication during pregnancy: A population-based study among 19,874 Danish women. Eur J Clin Pharmacol. 2006; 62: 547–553. https://doi.org/10.1007/s00228-006-0119-x PMID: 16673101
30. Stokholm J, Schjarring S, Pedersen L, Bischoff AL, Felsgaard N, Carson CG, et al. Prevalence and Predictors of Antibiotic Administration during Pregnancy and Birth. Thorne C, editor. PLoS ONE. 2013; 8: e82932. https://doi.org/10.1371/journal.pone.0082932 PMID: 24340068

31. van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MJCM. Domperidone and Ventricular Arrhythmia or Sudden Cardiac Death: A Population-Based Case-Control Study in the Netherlands. Drug Saf. 2010; 33: 1003–1014. https://doi.org/10.2165/11536840-000000000-00000 PMID: 20925438

32. Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010; 19: 881–888. https://doi.org/10.1002/pds.20652862

33. ANSM: Agence nationale de sécurité du médicament et des produits de santé. Rupture de stock de VOGALENE (metopimazine). [cited 2 Aug 2020]. Available: https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Rupture-de-stock-de-VOGALENE-metopimazine-Point-d-Information

34. National Health Service (NHS Digital). Prescription Cost Analysis—England, 2017 [PAS]. In: NHS Digital [Internet]. 2017 [cited 31 Aug 2020]. Available: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-cost-analysis-england-2017

35. WHO recommendation on interventions for the relief of heartburn during pregnancy. 28 Mar 2018 [cited 28 Sep 2020]. Available: https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/antenatal-care/general-antenatal-care/who-recommendation-interventions-relief-heartburn-during-pregnancy

36. Li CM, Zhernakova A, Engelstrad L, Wijmenga C, Brusselaers N. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. Aliment Pharmacol Ther. 2020; 51: 410–420. https://doi.org/10.1111/apt.15610 PMID: 31909512

37. AstraZeneca. Prilosec (package insert). 2012.

38. Bottomley C, Bourne T. Management strategies for hyperemesis. Best Pract Res Clin Obstet Gynaecol. 2009; 23: 549–564. https://doi.org/10.1016/j.bpobgyn.2008.12.012 PMID: 19261546

39. Centre de Référence sur les Agents Teratogènes (CRAT). Metopimazine—Grossesse et allaitement. [cited 28 Sep 2020]. Available: https://lecra.de/spip.php?page=article&id_article=58

40. Centre de Référence sur les Agents Tératogènes (CRAT). Metopimazine—Grossesse et allaitement. [cited 28 Sep 2020]. Available: https://lecra.fr/spip.php?page=article&id_article=58